Most sellers focus their attention on getting to completion. The transition period is what happens after completion — and for many sellers it is the part of the transaction they were least prepared for. Understanding what the transition period requires, what it does not permit, and how it interacts with the non-compete and earn-out provisions will prevent disputes and allow the handover to serve its purpose: protecting the goodwill the buyer has paid for.
What Is the Transition Period?
In most dental practice sales, the sale and purchase agreement includes a transition period — a defined period, typically three to six months, during which the seller remains involved in the practice in a support capacity. The length and terms of the transition period are negotiated as part of the SPA, and the seller is paid for their time — either as an associate, a consultant, or under a specific transition services agreement.
The defining feature of the transition period is that the seller is there to support, not to manage. From the moment of completion, the buyer owns the practice and has full authority over its clinical, operational, and financial management. The seller’s role during the transition is to introduce, hand over, and explain — not to run the business they have just sold.
This distinction matters practically. A seller who continues to behave like a principal during the transition period — making unilateral decisions about staff, overriding the buyer’s instructions, or dealing directly with suppliers or NHS England without authority — is acting outside the scope of their transitional role and potentially in breach of the SPA.
What the Transition Period Requires
Clinical Handover
The most important function of the transition period is the clinical handover. In most dental practices, a significant proportion of patient goodwill is personal — it is attached to the selling principal, not to the premises or practice name. The purpose of the clinical transition is to introduce patients to the incoming principal or new associate, to manage the transfer of active treatment plans, and to reduce the degree to which patients follow the seller out of the practice.
A well-managed clinical handover involves working alongside the buyer (or their nominated clinician) during the transition period so that patients have face-to-face contact with both; reviewing active treatment plans so the buyer has the clinical notes and context to continue treatment; and handling any urgent or outstanding clinical commitments that were in progress at completion.
Team Introductions
The selling principal is typically the most trusted figure in the practice team’s working life. Their departure represents genuine disruption — particularly for long-serving nurses, reception staff, and clinical coordinators. During the transition period, the seller’s role includes introducing the buyer to the team in a manner that transfers credibility and authority to the new owner.
A seller who remains the informal centre of authority during the transition — who staff continue to consult about decisions rather than the new owner — is creating a dependency that will become a problem the moment the transition ends.
Systems and Operations Access
The transition period typically includes handing over operational systems: patient management software access and data, supplier relationships, laboratory accounts, equipment service records, and software licences. For most practices this is a matter of practical transfer rather than extended handholding — it takes days rather than weeks. Specific systems, particularly bespoke NHS data configurations or practice management platforms with institutional complexity, may require more sustained support.
NHS Responsibilities During Transition
In practices with NHS GDS or PDS contracts, the seller often retains their performer number and continues delivering UDA activity during the transition period, operating under the contract now held by the buyer. This is one of the most commercially sensitive aspects of the handover: the seller is delivering NHS treatment on behalf of the buyer, generating income against the contract the buyer has paid for.
The SPA and any associated associate agreement should specify how this income is accounted for. Typically the seller is paid as an associate for clinical activity during the transition — on the same terms as any other associate. Any ambiguity in these arrangements is a common source of post-completion disputes.
Key Relationship Handovers
Relationship continuity — with the practice accountant, specialist referral networks, key supplier contacts, and NHS England relationship contacts — is part of the transition scope for most practices. For larger or more complex practices this is a material part of the value being transferred and should be treated as a discrete obligation in the SPA rather than assumed.
What the Transition Period Does Not Allow
Managing the Business Independently
The seller does not retain management authority after completion. The buyer is the owner and the decision-maker. The seller cannot agree contracts, vary employment terms, change supplier arrangements, or make clinical or operational decisions that affect the practice without the buyer’s express authority.
Sellers who find this difficult — who have run the practice for twenty or thirty years and instinctively reach for decisions — sometimes create significant friction during the transition period. The SPA is the authority that defines what the seller can and cannot do. If in doubt, ask the buyer rather than act.
Soliciting Patients
The seller’s post-completion restrictions on patient solicitation begin from the moment of completion — not from the end of the transition period. This is a point of consistent confusion and occasional dispute.
The non-compete and non-solicitation provisions in the SPA apply from the date of completion. The fact that the seller continues to work clinically in the practice during the transition period does not suspend or delay those restrictions. The seller cannot, during or after the transition, solicit patients of the practice — whether by letter, phone, social media, or informal conversation — for their own benefit.
Clinical Versus Administrative Sellers
The nature and length of the transition period depends significantly on whether the selling principal is a clinical principal or primarily an administrative one.
Clinical sellers — those who provided a substantial proportion of the practice’s clinical output — have the most work to do during the transition. Their patient relationships are the principal source of goodwill risk, and the clinical handover is the most material part of the transition. A clinical seller with a strong private patient list may need three to six months in practice to provide meaningful continuity.
Administrative sellers — those who primarily managed the practice rather than providing clinical services, or who had already significantly reduced their clinical activity before the sale — have a much lighter transition obligation. Their value during transition is operational and relational, not clinical. A one to three month administrative handover is typically sufficient.
Most SPA negotiators will align the length and intensity of the transition obligation with the seller’s clinical contribution to the practice. A seller who overstates their clinical role during the sale process and then seeks a minimal transition will face pushback from the buyer, who has priced goodwill on the basis of continuity.
The Transition Period and the Non-Compete
The non-compete and the transition period run concurrently from the date of completion. Both begin on completion day.
- A seller who agrees a six-month transition and a two-year non-compete will not be free to practise outside the restricted area until two years after completion — regardless of whether the transition ended at month three or month six.
- The transition period does not “use up” any of the non-compete period. They are separate contractual obligations that share a start date.
Sellers sometimes assume that completing their transition obligations ahead of schedule will shorten their overall restricted period. It does not. The non-compete runs from completion, full stop. A seller who wants to return to independent practice or take an associate position outside the restricted area should understand exactly when their restriction ends from the day the SPA is signed.
When the Transition Overlaps With an Earn-Out
In DSO or group buyer deals, the sale structure often includes an earn-out — a deferred consideration element contingent on the practice’s post-completion performance. Where an earn-out is in place, the transition period and earn-out period typically run concurrently, at least in part.
This creates a specific tension: the seller has an obligation to support the buyer’s operation of the practice (transition) and a financial interest in the practice’s performance during the same period (earn-out). If the seller believes the buyer is managing the practice in a way that reduces the earn-out outcome, they may be tempted to interfere in operational decisions.
The SPA should anticipate this tension. Anti-manipulation covenants — which require the buyer to operate the practice in good faith during the earn-out period without taking steps to minimise the seller’s earn-out — are the seller’s primary protection. The seller’s recourse is contractual and legal, not operational: they cannot override the buyer’s management decisions because they believe those decisions are affecting the earn-out.
Common Transition Period Disputes
Vague Obligations
The most common source of post-completion transition disputes is insufficient specificity in the SPA. Where the transition obligations are described in general terms — “seller will provide reasonable assistance” — both parties have different expectations of what that means. Disputes about availability, clinical hours, and the scope of knowledge transfer are all more likely when obligations are vague.
Sellers should push for the SPA to specify: the number of days or sessions per week the seller is required to be present, the geographic scope of that presence, the defined end date of the transition, and the mechanism for early termination by agreement.
Availability
Disputes about the seller’s availability during the transition are common. A seller who is eager to move on, or who has accepted a new position subject to non-compete clearance, may not be as consistently available as the buyer expected. If the SPA does not specify minimum availability requirements, the seller’s obligations are difficult to enforce and the buyer has limited remedies.
Completion Confirmation
Some disputes turn on precisely when “completion” occurred for the purpose of measuring the transition period and the non-compete start date. In transactions where completion documents were executed over multiple days, or where NHS novation was confirmed after the commercial completion date, the start date for both the transition and the non-compete may be ambiguous. This should be resolved explicitly in the SPA rather than left to be argued later.
Non-Compete Start Date
Because the non-compete begins on completion, any ambiguity about the completion date becomes an ambiguity about when the seller is free to practise without restriction. Sellers who want to return to independent practice or take an associate position outside the restricted area after the non-compete expires need to know precisely when the restriction ends. Any uncertainty in the completion date should be resolved in the SPA with a specific agreed date.
For a complete overview of the dental practice sale process, see how to sell your dental practice. For what buyers review before completion, see dental practice due diligence.
Get a free confidential dental practice valuation →
Frequently Asked Questions
What is the transition period after selling a dental practice?
The transition period is a defined period — typically three to six months — during which the seller remains involved in the practice in a support and handover capacity after completion. It is a paid obligation set out in the SPA. From the moment of completion, the buyer owns and manages the practice; the seller’s role is to support the handover, not to continue running the business.
Does the non-compete start after the transition period ends?
No. The non-compete begins on the date of completion, running concurrently with the transition period from day one. A two-year non-compete agreed in the SPA begins on completion day — not on the day the transition period ends. The transition period and the non-compete are separate obligations that share a start date.
Can I solicit patients during the transition period?
No. Post-completion restrictions on patient solicitation begin from the date of completion, not from the end of the transition period. Working clinically in the practice during the transition does not suspend the non-compete or non-solicitation provisions. Soliciting patients — whether by letter, phone, social media, or informal conversation — for your own benefit is prohibited from completion day.
What if the buyer is managing the practice badly during the earn-out?
Where an earn-out is in place and the buyer is managing the practice in a way that reduces the seller’s earn-out outcome, the seller’s remedy is through the SPA’s anti-manipulation covenants — not by overriding the buyer’s management decisions. A buyer who breaches their obligation to manage the practice in good faith during the earn-out period may be liable for the resulting loss.
What are the most common transition period disputes?
Vague obligation wording is the most common root cause. Disputes typically involve: the seller’s availability, what counts as adequate clinical cover, whether the transition was completed satisfactorily, and when the non-compete clock started running. Specificity in the SPA — defined hours, defined end dates, defined obligations — is the best prevention.